Pro-urokinase-type plasminogen activator is a substrate for hepsin
about
Toxin-based therapeutic approachesAllosteric antibody inhibition of human hepsin proteaseProstate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.Identification and characterization of small-molecule inhibitors of hepsinAssociation of hepsin gene variants with prostate cancer risk and prognosisAn allosteric anti-hepsin antibody derived from a constrained phage display library.Cleavage specificity analysis of six type II transmembrane serine proteases (TTSPs) using PICS with proteome-derived peptide librariesMatrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cellsTargeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodiesLow expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survivalLeukocyte cell surface proteinases: regulation of expression, functions, and mechanisms of surface localization.The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment.Hepatitis B virus X protein binding to hepsin promotes C3 production by inducing IL-6 secretion from hepatocytes.Plasmin-mediated proteolysis is required for hepatocyte growth factor activation during liver repair.Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.The role of type II transmembrane serine protease-mediated signaling in cancer.HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy.Effect of anthralin on cell viability in human prostate adenocarcinoma.Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.A novel mode of intervention with serine protease activity: targeting zymogen activation.Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.Molecular and physiological mechanisms of membrane receptor systems functioning.Inhibition of nuclear factor-κB signaling suppresses Spint1-deletion-induced tumor susceptibility in the ApcMin/+ model.The activity of a type II transmembrane serine protease, matriptase, is dependent solely on the catalytic domain.The serine proteinase hepsin is an activator of pro-matrix metalloproteinases: molecular mechanisms and implications for extracellular matrix turnover.Serine protease hepsin regulates hepatocyte size and hemodynamic retention of tumor cells by hepatocyte growth factor signaling in mice.Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.The role of hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2 in endometrial cancer.
P2860
Q27013664-68332B40-8F8D-48CF-BFDE-1D96425E08FCQ27675904-9EBF732C-53F4-4917-9DB3-A9E6635FCE5CQ30409623-C7DC4AF8-2663-4642-B63B-9B2091737A10Q30540234-535C8D3B-9314-4271-9D4F-067C71687221Q33375569-71C57A90-FFD1-4675-B2E9-02F77512B3DBQ33872480-E0278A59-9DCA-462F-9D59-B574BFB6F899Q34132742-730A2208-9801-443D-8891-D458376C2FE8Q34165943-12BF9390-F1B2-4129-986F-409312FD79C4Q35095228-9B0A6944-6979-4342-9347-5E92A69A1653Q35238060-F327E96C-D86A-4158-AA95-C29988227722Q35431906-250AD323-6880-4FBB-AD91-38CBCFEF8378Q35642678-C8C8C27C-48B5-44C5-BB59-42CD2CB434B6Q36715904-AC6B3E2D-66F0-40AF-A5CC-A07CF00C2B99Q36923138-9DA0AA42-000B-46D0-A706-AF3459C03155Q36946624-A7AB8852-C483-4358-816F-FC0A9A630B33Q37176420-4B84C08B-4442-49C1-9A09-BA996B39712DQ37801943-80C401A3-D235-4076-A17E-B4C921CDCDA1Q38184632-0C5D1DD3-73A7-43F9-8DAA-6B2B884CA07AQ39015415-F84ACD90-DEDB-4838-8492-3DFD352D2B7DQ39145828-B86736DE-7ACF-463A-BEC8-D92530216D4CQ39301892-BBA195FA-4BDF-4E75-A9EE-F1044E111D0CQ39326983-5E99AA97-21D9-4DE6-AAC4-582F15365E31Q39910451-D773FFB7-A81B-4058-BBBD-C8C7DFD7513FQ39941224-F10A2564-7786-4CA7-AFC1-F0B95D52F8B6Q42153161-AFC32758-181A-425A-AA84-B3904B319D87Q42254033-6C95872C-160C-4248-9A0D-EF4ADA309A25Q45904382-EEE5493C-8C56-41D8-BB1F-FDA112CE5DE2Q47168535-97C5F2D5-FB48-4411-B980-932F932B92E8Q47315721-F91E459C-4A01-49E2-AA2B-1CDCFC0DAC34Q52661781-3E4E7CE5-1F1A-4A42-BE5E-A1825C916D3AQ54415251-198E3FED-0DF0-4E5C-B6FD-3F6B63E7EF30
P2860
Pro-urokinase-type plasminogen activator is a substrate for hepsin
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Pro-urokinase-type plasminogen activator is a substrate for hepsin
@ast
Pro-urokinase-type plasminogen activator is a substrate for hepsin
@en
Pro-urokinase-type plasminogen activator is a substrate for hepsin
@en-gb
Pro-urokinase-type plasminogen activator is a substrate for hepsin
@nl
type
label
Pro-urokinase-type plasminogen activator is a substrate for hepsin
@ast
Pro-urokinase-type plasminogen activator is a substrate for hepsin
@en
Pro-urokinase-type plasminogen activator is a substrate for hepsin
@en-gb
Pro-urokinase-type plasminogen activator is a substrate for hepsin
@nl
prefLabel
Pro-urokinase-type plasminogen activator is a substrate for hepsin
@ast
Pro-urokinase-type plasminogen activator is a substrate for hepsin
@en
Pro-urokinase-type plasminogen activator is a substrate for hepsin
@en-gb
Pro-urokinase-type plasminogen activator is a substrate for hepsin
@nl
P2093
P2860
P921
P356
P1476
Pro-urokinase-type plasminogen activator is a substrate for hepsin
@en
P2093
Daniel Kirchhofer
Paul Moran
Rajesh Vij
P2860
P304
P356
10.1074/JBC.M605440200
P407
P577
2006-10-13T00:00:00Z